Khartis Therapeutics officially emerged from stealth with a $50 million Series B that brought its total funding to $95 million, led by Forge Life Science Partners with Longwood Fund and Lilly Asia Ventures among others. The company’s lead program is an oral small-molecule candidate targeting IGF-1R for thyroid eye disease (TED), with plans to start a clinical trial in the first quarter of 2027. The TED asset is designed to avoid infusion-based administration used by existing IGF-1R-directed therapies such as Amgen’s Tepezza and Viridian Therapeutics’ Lumvoa, which have raised safety and convenience tradeoffs tied to IV delivery. Khartis is aiming for a more patient-friendly dosing option through oral targeting. Khartis also disclosed multiple earlier-stage internal programs beyond the TED lead, but the funding focus is centered on advancing differentiated small molecules into clinical testing. The investment reflects continued appetite for differentiated routes to established targets, particularly where a switch from intravenous to oral delivery can materially change the clinical workflow and potentially broaden access.